5409-58-5Relevant articles and documents
PROCESS FOR THE PREPARATION OF BEDAQUILINE FUMARATE
-
Page/Page column 9, (2020/08/22)
The present disclosure relates to an improved process for the preparation of bedaquiline fumarate, comprising a step of preparing bedaquiline by reaction of 3-benzyl-6-bromo-2-methoxyquinoline 5 with 3-(dimethylamino)-l-(naphthalen-l-yl)propan-l-one 4 in the presence of lithium pyrrolidide.
Synthesis and anti-tubercular activity of conformationally-constrained and bisquinoline analogs of TMC207
Kalia, Dimpy,Anil Kumar,Meena, Gajanand,Sethi, Kashmir Prasad,Sharma, Rohit,Trivedi, Priyanka,Khan, Shaheb Raj,Verma, Ajay Singh,Singh, Shyam,Sharma, Sandeep,Roy, Kuldeep K.,Kant, Ruchir,Krishnan, Manju Yasodha,Singh, Bhupendra N.,Sinha, Sudhir,Chaturvedi, Vinita,Saxena, Anil K.,Dikshit, Dinesh K.
, p. 1554 - 1563 (2015/08/24)
One of the most significant breakthroughs in the battle against tuberculosis is the recent approval of the quinoline compound, TMC207, for the treatment of drug-resistant tuberculosis. To gain insight into the molecular determinants of the activity of TMC207 and to evaluate the scope of quinoline compounds as anti-tubercular agents, we synthesized a series of TMC207 derivatives and evaluated their anti-tubercular activity. Making the lateral chain of the drug rigid by linking it to an adjacent phenyl substituent resulted in a decrease in activity. In contrast, replacing a phenyl substituent of TMC207 with a quinoline moiety gave bisquinolines that demonstrated potent anti-tubercular activity in in vitro experiments, in ex vivo mouse bone marrow macrophage assays, and also in the in vivo mouse model of the disease. These results provide new guiding principles for modifying the TMC207 scaffold to develop efficacious anti-tubercular drugs and set the stage for the development of bisquinolines as a promising new class of anti-tubercular agents.
DIHYDROIMIDAZOTHIAZOLE DERIVATIVES
-
Page/Page column 38, (2008/06/13)
Compounds of formula (I): or pharmaceutically acceptable salts thereof, exhibit 5-HT1A agonism in addition to noradrenaline reuptake inhibition and optionally also 5-HT reuptake inhibition are useful for the treatment of obesity.